Skip to main content
CYTK $51.65 -2.86%
CYTK logo
CYTK · Cytokinetics Inc
Track CYTK — free
Market Cap
$7.20B
Shares
139.30M
Volume · Nov 17 2.71M Avg daily vol (3M) 2.01M
All webcasts

Conference · 2026-11-16

Cytokinetics Inc (CYTK) November 16, 2026 Conference Transcript

Concluded Nov 16, 2026 Audio replay
Nov 16, 2026 32:00 35 turns
Period
2026-11-16
Runtime
32:00
Sources
2 artifacts

Transcript & audio

32:00 Audio
Analyst

Good day, everybody. So next session here at UBS Biopharma conference is cytokinetics. Very excited to have the whole team here. Just quickly, Robert, thank you so much for joining us. Fari, Andrew, and Song, this is really amazing. Thanks for joining our conference. Maybe, Robert, if you can give us a brief outline of what are some of the highlights coming out of the third quarter earnings. I think people know the story very well, but just if you can hit on some of the key points that you outlined.

Sure. So coming out of Q3 earnings, we feel like we're executing very, very well on our commercial launch of MyCorso. With focus to the U.S., but also with inclusion of Germany and soon other countries to follow as it relates to the U.S. We believe we're delivering against all of the metrics and objectives, the KPIs that we laid out for the street earlier in the year. My colleagues can speak to them in detail, but as it relates to demonstrating that we are having effect to increase the prescribing of cardiac myosin inhibitors category growth at the same time we are climbing in preferential share of new scripts. We think we're demonstrating that mycorso, as differentiated, is meaningfully impacting the disease OHCM, but still with plenty of upside. Even altogether, BMS and cytokinetics work now with... Camzyos and Mycorza, respectively, we still have upwards of 80% of symptomatic diagnosed OHCM patients in the United States who are not receiving a cardiac myosin inhibitor. This morning, we announced that the U.S. FDA has... Approved our FNDA to be enabling of data from Maple HCM to be included in an expanded label for Mycorso. Why is that important? It's especially important because the bar was already very high. The data from Sequoia, the original pivotal study of mycorso, informed a label that included all patients with OHCM with or without the beta blockers. So one asks why then submit the MAPLE data. FDA is now permitting of inclusion of MAPLE data, as could be enabling of further differentiation for mycorso. MAPLE was a study of monotherapy afecampton versus monotherapy metoprolol, and now we have in the label data to suggest why mycorso could be considered as an alternative to a beta blocker. Now, keep in mind, we believe, and as we've been guiding all along, we think this is incremental because the label already included all of OHCM. But for these data now in label, add to that our expectation that next year the guidelines may be updated to reflect MAPLE data and elevating AFI-Campton in the step editing of patients around OHCM. And we think this could be, together, transformative at that time. So I think all of this combined underscores cytokinetics as doing what it said it was going to do. Executing well on the commercialization of MyCorso, expanding the label to include Maple HCM, and next up is, as we guided, submission of an SNDA inclusive of Acacia data, and as that could be factoring into label next year. So it's incumbent upon us to continue to pioneer and lead, and we think we're doing just that.

Analyst

Great. Awesome. So yeah, I think, thanks a lot for that. And yeah, and congrats on the first line approval. Maybe I'll start there. I think it's interesting that, so you mentioned that the guidelines could get updated next year, but the payers would still step at it through the beta blockers. I'm surprised that the, you know, there is so much resistance in the payer community. This is not a massive market, right? But when you think about that, the data that we have seen, beta blockers are actually hurting patients. So, I've been just thinking, like, what is the argument that you hear from payers in terms of, let's say, not putting CMI's first line, for my course of first line, given that we've seen such an amazing data, and if the guidelines also get updated, then what would be their response to not use it?

So like with anything else, there's inertia. And inertia gets chipped away with more and more evidence, more and more time. So maybe Andrew could speak to payer feedback in connection with these matters, and then Fatty could speak to physician behavior.

So, I mean, payers are certainly leading on guidelines as kind of their argument for why have utilization criteria around trying a beta blocker first or a physician attesting that a beta blocker has been tried or the patient can't take it. So payers, this category and all categories, typically we'll put up. There's challenges to make sure that appropriate patients are taking therapies that are more costly than what physicians have used historically. I think it's probably in our best interest for now to more accelerate the addition of a CMI as compared to take on payers to try for monotherapy. If we did that, I think there'd be a lot more contracting, rebating, market access would be more challenging than it is as a category. So I think as Robert said, inertia, data, over time, especially if NHCM is approved, that guidelines get updated, you may set criteria loosened, but not in the next year, two years.

Fady Malik Other

Yeah, I think the, you know, to influence patient physician behavior, step one is to generate High quality data. And with my Corzo, you know, we now have Sequoia, we may pool, we have Acacia, forest data. The guidelines were written on expert opinion because there was no high quality data for the use of beta blockers or everything else. That's not a position. I mean, they accommodate expert opinion because sometimes there's nothing else to fall back on. But the field is being transformed by now the availability of high-quality randomized controlled clinical data. Um, so they, um, um, I expect, uh, will be updated to reflect that in the, uh, the next version, which we expect in 2027. Guidelines then help influence physician behavior because the guidelines are the ultimate kind of peer review and, and, and your peers have now voted to. Physician things a certain way. And physicians, you know, I think they incorporate that into their practice as well. Most of the, you know, truly expert physicians have moved. They don't wait for the guidelines. They've already moved to implement in their practice that the data that have been presented and published now.

But I think the net-net of what you're hearing from Andrew N. Fadi is that... Payers will come along when they see physician behavior altering and the use of Affecampton more frontline. In the meantime, physicians, knowing of this payer headwind, will likely be moving more swiftly through beta blockers, step editing through them more rapidly in order to be able to get their patients sooner on Affecampton.

Analyst

Great. Okay, perfect. And then maybe if we talk about the, you know, the launch updates on OHCM. So you've noted 9,000 adjustable patients in the CMI category, also seeing more than 3,000 ads per quarter. So pretty impressive metrics. Just like when you think about, you know, fourth quarter or next year, is this growth momentum going to continue? And how do you sort of sustain this growth in the subsequent quarters?

I'm going to answer your question, but I'm going to start a little farther back. So if you think about where we were this time a year ago. Will MyCorso get approved? If it gets approved, will it have a differentiated risk mitigation profile? And if launched, how are you going to compete with BMS? Think about where we are now. MyCorso is approved. It has a differentiated label and REMS. And at the same time, we're demonstrating, even as audacious as we set goals, To have a preferential share of new scripts within six to nine months, we're getting to a place where I think this is demonstrating to be a very strong commercial launch and with plenty of upside still remaining in the market that is still not yet penetrated. So we set at the beginning of the year these KPIs. I'm going to ask Andrew to answer your question and where we are relative, but I think there's tremendous momentum building, tremendous momentum building for my Corzo and the work that we're doing. And as we, even as a small company working in a category that BMS has been in for four years, we're demonstrating that we're a leader.

Yeah, so growth is really fueled by new prescribers. Yeah, so I think in the third quarter on our earnings call, we highlighted that over 70% of the market growth is because of what were previously naive to CMI prescribers. There are, when we sized our field force, we looked at those who treat and diagnose HCM. Obviously, before CMI, that was largely with beta blockers. So we are targeting and in the U.S. discussing mycorza with these 11,000 physicians. There's only around maybe 2,500 who prescribe today. And as that number grows, you're going to see the category grow as well, because there's a lot of patients in community that don't go to the large centers, don't go to academic centers. But we're also seeing growth in the large academic centers. 30% of the growth was there as well. So we are expecting the market to continue to grow. Maple should accelerate some level of growth, especially in the community. Acacia will be a much larger growth driver for the CMI category overall. If you think about the community, that doubles on average the population size of patients because it's a 50-50-0 versus end split. The market, if you look at market nine months year to date, this year versus last year, the market grew about 50% overall, and again, most of that is because of new prescribers. So, continue to... We're going to accelerate growth within the category of that concentration of high prescribers, but at the same time, expand utilization. And that's what we've said even before our launch, what it's going to take for this category to be in the multi-billions that we know that it can be.

Analyst

Yeah, yeah, that's great. Okay, and then if you focus on some of the ex-US launch updates, so you've seen a few approvals now, China, EU, UK, Canada, just sort of early stage in these launches, but yeah, how do you expect the ramp to be for these categories?

I do think that, putting it into context, The China business, the Europe business, they together are still not going to represent more than 10 to 20 percent of the total U.S. business. So with that caveat, we do think it's important to ensure that Mycorso is made available to patients all over the world. It is available now in China. It is available in Germany and in this quarter launching in the U.K. Today, next year, we expect by the end of the year to be ensuring that Mercorzo is available throughout all of the major markets of Europe and over time, even beyond the major markets. So we do think that this is a global launch. We've taken on something that a lot of biotech companies in the U.S. are reluctant to do, which is go to market globally. We think through our own actions and through that which our partners are doing, we're doing right by science, medicine, and patients to make MyCorso available globally. And in every country where we're operating, keeping in mind our fiduciary obligations and understandings of the economics, we expect we can build a profitable business in every country. Even as there's pricing differential between countries. So Andrew can speak to how we're doing, but in Germany, we're demonstrating that we can compete very effectively.

Yeah, Germany is the market that has launched where we're commercializing, and Germany is already over 50% in new-to-brand share just a few months into launch, and they've had three months in a row of that level of performance. So Germany is doing extremely well on the market. As Robert said, the UK is launching this quarter, France in the first quarter. Germany and France are half of Europe overall in terms of value. So, um, we're expecting to have. Eight additional launches next year in Europe. So next year is a big year for Europe overall. It's equal in size to patient volume in the U.S., but because of the pricing difference, that's where we'll be 15% of our overall revenue a few years out when we start to get Europe growing on a country-by-country business. But we're very pleased with our European team. We're very pleased with our uptake. And, you know, we're continuing to see growth in each of these markets as our expectation. Great.

Analyst

So maybe just switching gears to, I know there's been a lot of just investor discussion around the competitor updates that we've seen on the trial design, and this has taken a life of its own, so I'm really surprised how much your stock has traded around this. But it seems like, yeah, so this whole concept of that, okay, like now they've proposed three echoes, but not ready for titration. I want to hear your perspective, like what are investors missing on this? Because it seems like it is having an impact on your stock. But I'm curious to understand, like, the differentiation that the competitor has proposed based on the trial design, why is that or not a differentiation based on how you look at it?

Sure. So there's a concept. In science and research and development, signal to noise. I think there's a tremendous amount of noise around this space and theoretical differentiation that I think is not representative of signal. And in time, signal rises above noise. What we're hearing from companies that purport to be followers... Is that through work that they're doing, they may be in a position to capture some of the white space around which my Corzo in the marketplace may leave open opportunity. And that would be potentially three, four, five years down the road, representative of an opportunity that somehow will escape us. I want to be clear, as the pioneer and leader, there's nothing that's been spoken that we're not already well intentional to executing to be enabling of cytokinetics to continue to maintain its leadership. Whether that's time to optimal dose, whether that's a differential number of echoes, and what that may mean for REMS, these are all things that, with the combination of registries, physician-sponsored studies, Phase 4 studies that we may sponsor, real-world evidence, we're already demonstrating that we believe we'll be able to achieve. I'm going to ask each of Fatty and Andrew to speak to this in the context of what are the prevailing doses of Afi-Campton currently demonstrating leadership in this space, 5-10 milligrams primarily maintained, And how, over time, we may see an evolution of REMS and label for mycorso.

So, just from a dosing point of view, you know, we have over 1,000 patients who are on their maintenance dose when we looked a few months ago at a data cut, and 50% of those patients are on 5 milligrams on a maintenance dose, and 30% on 10, so 80% are on 5 or 10. And if you take, if a patient's on five milligrams, They start at 5 milligrams. They get an echo. If the echo is confirmatory, that 5 is the right dose. They get an echo most as long as their EF is over 55. They're six months out. So you have two echoes in a single year for half of our patients that are on that 5 milligram dose and three echoes if you're on that 10 milligram dose. So I think we're saying in the real world as well, we're not titrating every two weeks. Like we did in the clinical trial, we have a two to eight week window that is a differentiator in terms of labeling. And generally, physicians are taking longer than four weeks with patients to titrate up. So that's what we're seeing in the real world. And we're certainly going to, you know, discuss how we leverage and communicate that to physicians so they understand what we're seeing in terms of dosing.

Fady Malik Other

Yeah, I think the other concept is that physicians use echoes to help guide therapy because it's a measure of how effective therapy is. In the absence of measuring gradients, you know, you can talk to patients. If any of you have done that, I did that for many years. Very difficult to suss out, you know, of a patient exactly whether they're feeling better, they're not feeling better. You like objective data, and the ECHOs provide some objective data. What you want, really, is flexibility about using them. How do you use them? When do you use them? As Andrew pointed out, physicians are using 5 and 10. They're finding that their patients are, in many cases, feeling better. The numbers are getting better, and they are, you know, staying pat for a while. So, you know, playing it forward. Three, four years from now, there'll be tens of thousands of patients on apicampton. There will be tens of thousands of patient years of experience. The data supporting long-term effectiveness, effects on remodeling, all those kinds of things, you know, they take time to generate, and that body of evidence will be established for... For Affecampton. So I think there will remain, you know, a large differentiation between two medicines, even if all the unknowns. About them in terms of safety profile, AFib profile, you know, how will they ultimately be in, you know, all of those things, even if they best case scenario, you know, as we see, we think Apicampton is highly effective medicine. It doesn't get 100% market share overnight. It takes time.

The other thing I'll add is, if you've been a good student of this marketplace, you understand that a protocol is not a label. If you look at the Explorer study that Myocardia conducted with Mavicampton, the way they dosed Mavicampton in that pivotal study is very dissimilar from the way ultimately FDA and the Division of Risk Management imposed a REMS. If you look at our study, we had no dose interruptions in Sequoia, but FDA still, after a while, decided it was necessary to have a REMS. It wasn't the cardiorenal division that decides that. It's the division of risk management within FDA. So I wouldn't over-interpret or extrapolate beyond information provided in the start of a Phase III study for what that ultimately might look like in the way of a label. I think precedent would suggest that any third or fourth entrant coming into a category is more likely to have a restrictive REMS than to have a less restrictive REMS. And we believe very much so, and based on conversations with FDA and precedent, that the way to relax and remove a REMS is not through a Phase III study, but through real-world evidence.

Analyst

Yeah, and we've seen that, you know, Bristol did that, right, for chemziose. I think some of the things that you're alluding to here, just that the, you know, in real world, the data has been much better compared to the clinical trial on these 5-mig, 10-mig doses. I'm just curious to understand, you know, how long or what level of evidence would FDA need to look at to, let's say, supposedly relax the label, you know, criteria. And then my course, I think from the time when they launched to when the label was updated, I think it was three and a half years, I believe.

Fady Malik Other

Chemzius, yeah.

Analyst

Chemzius, sorry. So, yeah, if you can just help us understand, I mean, you launched this year, you know, how much – yeah, is there any certain threshold at these many patients, or what do you need to show to approach the FDA with that?

Before I ask that, I'd comment. I might just say it took BMS and with ChemZios three years. to get a relaxation of the REMS, but also the adoption curve was different. We already this year are demonstrating three to four times more patients on mycorso than were on camziose in its first six to nine months. With that said, it still takes thousands of patient years of experience, and then maybe Fatty can speak to our strategy.

Fady Malik Other

Yeah, there's a big difference between a clinical trial that has 150 patients on drug for six months, that's 75 patient years, as opposed to 8,000 to 9,000 to 10,000 patients on drug, even for a year. Huge difference in the real world. And so those data, first of all, will inform safety profile quite more extensively than we even generate in our clinical trials. And we expect, you know, from what we're seeing already in the REMS, an excellent safety profile, you know, if anything as good or better than we saw in our clinical trials, low burden on patients. Uh, safety, uh, to be able to take those data to FDA, a couple of years timeframe, two and a half, it's hard to say. There's no specific, uh, you know, you just approach them when you think you're ready and, and you're going to go from there. And our, you know, our goal is to ensure we have a very solid.

And I encourage investors to go to school on precedence in this area where there were REMS and what it took to reduce or remove REMS. We certainly are good students of that history, and we're applying it in the way we approach the collection of real-world evidence with mycorso. One of the advantages of having a REMS is every one of those patients is tracked longitudinally, and those data get reviewed, analyzed, and submitted to FDA as part of an annual reporting process. So we're on top of all of that. Great.

Analyst

I'll just ask if there's any question in the audience. I'll have a few after that. If not, then maybe, yeah, just a quick clarification. Just by the nature of it, the echo that's done for titration, is that in any way different compared to the trial initiation echo in the end of trial? Is there a big difference?

Fady Malik Other

Oh, very, very different, I think. In just titrating the drugs, physicians are… They're, they're instructing their echo labs to just measure what we need to know. You know, an echo can measure a hundred different things, but you only really need to know two things. And so they're what we call limited echoes. We had them in the, in even Sequoia and Acacia that during dose titration, we had a much shorter protocol. For measurements we made, and then a more extensive protocol after dose titration was complete. So there's a lot of, you know, efficiencies that are gained through experience.

Analyst

Yeah, perfect. And then let's talk about non-obstructive side. So, yeah, so you have this filing going in at a certain point of time. Yeah, any label consideration or launch uptake dynamics that you want to call out compared to OHCM, how it has played out?

Fady Malik Other

Well, so we are on track to submit our supplemental NDA this quarter, as we guided to on our last earnings call, and the review process will take place. We are very optimistic around, as we, you know, look at support in the patient and physician community and their enthusiasm, strength of the data in Acacia. When you look at the safety profile, we acknowledge it was different, but when you look at how... After Campton was employed, one of these patients moved into the open-label extension, even the ones that were drug-naive in Acacia, the incidence of heart failure events was much lower. And so again, in, in, in, um, We expect all of that. We've made that, you know, very clear and evident in the documents that we're submitting. The, you know, the implementation of it in the REMS is likely within the same REMS. It's a bit of a, you know, you need to add a couple things here and there, not very, not really additional complications. You need to train the physicians on the new indication and those sorts of things. But, you know, if all goes well, then we'd expect an approval by hopefully this time next year.

Turn it over to Andrew. Before we ask Andrew to comment, because he's engaged some key opinion leaders and others around market research for NHCM. I do think the street is. I'm underestimating the impact and the potential for my Corzo in NHCM. If you go back to where we were and anticipating a potential approval in OHCM, quite a significant more refinement of models and analyst estimates and investor forecasting in and around OHCM. Seems to me that work is still to be done in HCM, where we will be the only, if approved, cardiac myosin inhibitor that has approval across the full spectrum of HCM, inclusive of gradients or not, obstructive or not, and that's where I believe there's tremendous upside that is potentially needing to be better acknowledged. Andrew, maybe you can comment on feedback you've received in and around the target product profile from AfiCampton and NHCM.

So there is a good deal of excitement from physicians about having an option to treat patients. When we looked at those that are CMI-experienced physicians, many of them anecdotally have told us they have patients that they are waiting to treat if the product's approved, and then we're also expecting, based on what these physicians told us, An acceleration of launch for NHCM with that subset of experienced CMI physicians. The reaction has been quite positive on the overall profile of the medication. Obviously, there are those that are New York car class 2, 3, those that are symptomatic. They're the ones that they'll focus on, which is not any different than OHCM. Currently, we're updating our disease awareness campaigns to cover HCM overall, and we're doing market research around our campaign and how we will roll out NHCM so we're ready if we get approved by this time next year.

And maybe before we run out of time, I might just ask Sung to comment. Cytokinetics is a company that takes very seriously the way we access and deploy capital and the way we're managing to those sorts of economics and metrics that matter to shareholders. And maybe Sung can speak to that for the business.

Sung CFO

Sure, absolutely. So we'll continue to be very disciplined with our capital allocation. As you know, we maintain a very strong balance sheet, $1.6 billion at the end of the last quarter. This will come in very handy as we continue to launch MicroZone in the U.S. But we have important launches in Europe, as Andrew and Robert mentioned earlier. But in addition to the commercial launches, it's very important that we maintain a robust pipeline. This is what we'll continue to be focused on with our capital allocation.

And we are investing very, very substantially in advancing and augmenting pipeline, and I think in 2027, we'll have a lot more to say about that.

Analyst

Perfect. With that, it's a wrap. So thank you so much, everybody, for joining, and looking forward to hearing more about the story.

Thank you.

Analyst Q&A · 1 question
Full-screen source Call document